ClinicalTrials.gg
CompletedNCT03523117Updated Jun 22, 2022Results posted

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

A Phase 3 interventional study of Ferric carboxymaltose and Ferrous Sulfate in Iron Deficiency Anemia, sponsored by American Regent, Inc.. Completed at 16 sites in United States. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2022-06-22.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
30th of 57
79 · median 100
Started
2019
with 6 others
Phase 3
16 of 57
none open now
Registered
28th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 30th largest by enrollment, is one of 7 that started in 2019, is one of 16 in phase 3, and was the 28th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate the efficacy and safety of intravenous ferric carboxymaltose (FCM), compared to oral iron, in pediatric participants who have iron deficiency anemia.

Read the detailed description

This is a Phase III, multicenter, randomized, active-controlled study that compares the efficacy and safety of FCM to oral iron in pediatric participants with IDA and a documented history of an inadequate response to oral iron therapy at least 8 weeks (56 days) prior to randomization.

Participants who satisfy the inclusion requirements and no exclusion criteria will be eligible to participate in this study and enter into a screening phase to confirm eligibility. Randomization will occur via the Interactive Response Technology (IRT) system in a 1:1 ratio to either Group A, participants receiving FCM, or Group B, participants receiving oral iron (oral solution drops, elixir or oral tablets). Randomization will be stratified by baseline Hgb (\<10, ≥10 g/dL) and age (1 to \<12 years and ≥12 to 17 years).

The oral ferrous sulfate formulation received will be based on the participant's age, such that infants and children (1 to \<4 years of age) will receive ferrous sulfate drops, children (≥4 to \<12 years of age) will receive ferrous sulfate elixir, and adolescents (≥12 to 17 years of age) will receive ferrous sulfate tablets. Participants who experience adverse clinical symptoms due to the oral iron during the treatment phase may have a weight-based dose of ferrous sulfate reduced from 6 mg/kg to 3 mg/kg. If the participant is receiving tablets, the dose will be reduced from one tablet taken twice daily to one tablet per day.

Once randomized, all participants will return for efficacy and safety evaluations, including adverse events and laboratory assessments, on Days 7, 14, 28, and 35. Additional pharmacokinetic sampling and analyses will be performed for participants receiving FCM on Days 0 and 7.

03

Conditions studied

  • Iron Deficiency Anemia
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants 1 to 17 years of age with assent to participation and his/her parent or guardian is willing and able to sign the approved by the Independent Review Board / Ethics Committee.
  2. Screening \<11 g/dL.
  3. Screening ferritin ≤300 ng/mL and transferrin saturation (TSAT) \<30%.
  4. Participants must have a documented history of an inadequate response to any oral iron therapy for at least 8 weeks (56 days) prior to randomization.
  5. For participants who are receiving an erythropoietin stimulating agent (ESA): stable ESA therapy (+/- 20% of current dose) for at least 8 weeks prior to the qualifying screening visit and no ESA dosing or product changes anticipated for the length of the trial.
  6. Participants undergoing treatment for inflammatory bowel disease (IBD) must be on stable therapy for at least 8 weeks prior to consent.

Exclusion criteria

Exclusion Criteria:

  1. Known history of reaction to any component of FCM.
  2. Previous randomization and treatment in this study or any other clinical study of FCM or VIT-45.
  3. History of acquired iron overload, hemochromatosis, or other iron accumulation disorders.
  4. Chronic kidney disease participants on hemodialysis.
  5. History of significant diseases of the liver, hematopoietic system, cardiovascular system, psychiatric disorder, or other conditions which, on the opinion of the investigator, may place a subject at added risk for participation in the study.
  6. Any existing non-viral infection.
  7. Known history of positive antigen (HBsAg) or viral antibody (HCV) with evidence of active hepatitis.
  8. Known history of positive -1/HIV-2 antibodies (anti-HIV).
  9. Anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy and vitamin B12 or folic acid deficiency) that has not been corrected.
  10. Intravenous iron and /or blood transfusion in the 4 weeks prior to consent.
  11. Administration and / or use of an product (drug or device) within 30 days of screening.
  12. Alcohol or drug abuse within the past six months.
  13. Female participant who is pregnant or lactating, or sexually active female who are of not willing to use an acceptable form of precautions during the study.
  14. Unable to comply with study procedures and assessments
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Active comparator
    Ferric Caroboxymaltose

    Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.

    Drug: Ferric carboxymaltose

  • Active comparator
    Oral Ferrous Sulfate

    Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants \<12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to \<4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to \<12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.

    Drug: Ferrous Sulfate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin g/dL

    Change in hemoglobin g/dL from baseline to day 35 will be analyzed using parametric analysis of covariance (ANCOVA). The model will include terms for the randomization strata (hemoglobin and age categories), baseline hemoglobin, as well as treatment group. Baseline hemoglobin will be defined as the last hemoglobin obtained before randomization.

    Time frame: Baseline to day 35

Secondary outcomes

  1. Change in Ferritin µg/L From Baseline to Day 35

    Change in ferritin µg/L from baseline to day 35 was analyzed using parametric analysis of covariance (ANCOVA). The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a covariate.

    Time frame: Baseline to day 35

  2. Change in TSAT (%) From Baseline to Day 35

    Change in TSAT (%) from baseline to day 35 was analyzed using parametric analysis of covariance (ANCOVA). The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a covariate

    Time frame: Baseline to day 35

  3. Change in Reticulocyte Hemoglobin (Picograms) Content From Baseline to Day 35

    Change in reticulocyte hemoglobin (picograms) content from baseline to day 35 was analyzed using a mixed model repeated. The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a reticulocyte hemoglobin content.

    Time frame: Baseline to day 35

07

Results

Posted Jun 22, 2022

Participant flow

Participant flow — Overall Study
MilestoneFerric CaroboxymaltoseOral Ferrous Sulfate
Started4039
Completed3937
Not completed12

Outcome measures

PrimaryChange in Hemoglobin g/dL

Change in hemoglobin g/dL from baseline to day 35 will be analyzed using parametric analysis of covariance (ANCOVA). The model will include terms for the randomization strata (hemoglobin and age categories), baseline hemoglobin, as well as treatment group. Baseline hemoglobin will be defined as the last hemoglobin obtained before randomization.

Time frame:
Baseline to day 35
Reported as:
Least squares mean · g/dL
Change in Hemoglobin g/dL
g/dLFerric CaroboxymaltoseOral Ferrous Sulfate
Change in Hemoglobin g/dL2.22 (1.69 to 2.75)1.92 (1.43 to 2.41)
Statistical analysis
  • Ferric Caroboxymaltose vs Oral Ferrous Sulfate · ANCOVA · p = 0.3108 · Mean difference (final values): 0.30
SecondaryChange in Ferritin µg/L From Baseline to Day 35

Change in ferritin µg/L from baseline to day 35 was analyzed using parametric analysis of covariance (ANCOVA). The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a covariate.

Time frame:
Baseline to day 35
Reported as:
Least squares mean · µg/L
Change in Ferritin µg/L From Baseline to Day 35
µg/LFerric CaroboxymaltoseOral Ferrous Sulfate
Change in Ferritin µg/L From Baseline to Day 352.22 (1.69 to 2.75)1.92 (1.43 to 2.41)
Statistical analysis
  • Ferric Caroboxymaltose vs Oral Ferrous Sulfate · ANCOVA · p = 0.0001 · Mean difference (final values): 0.30
SecondaryChange in TSAT (%) From Baseline to Day 35

Change in TSAT (%) from baseline to day 35 was analyzed using parametric analysis of covariance (ANCOVA). The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a covariate

Time frame:
Baseline to day 35
Reported as:
Least squares mean · percentage
Change in TSAT (%) From Baseline to Day 35
percentageFerric CaroboxymaltoseOral Ferrous Sulfate
Change in TSAT (%) From Baseline to Day 3524.30 (19.19 to 29.41)8.66 (3.70 to 13.63)
Statistical analysis
  • Ferric Caroboxymaltose vs Oral Ferrous Sulfate · ANCOVA · p = 0.0001 · Mean difference (final values): 15.64
SecondaryChange in Reticulocyte Hemoglobin (Picograms) Content From Baseline to Day 35

Change in reticulocyte hemoglobin (picograms) content from baseline to day 35 was analyzed using a mixed model repeated. The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a reticulocyte hemoglobin content.

Time frame:
Baseline to day 35
Reported as:
Least squares mean · picograms
Change in Reticulocyte Hemoglobin (Picograms) Content From Baseline to Day 35
picogramsFerric CaroboxymaltoseOral Ferrous Sulfate
Change in Reticulocyte Hemoglobin (Picograms) Content From Baseline to Day 356.95 (6.21 to 7.70)4.90 (4.15 to 5.65)
Statistical analysis
  • Ferric Caroboxymaltose vs Oral Ferrous Sulfate · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): 2.06

Adverse events

Collected over Day 1 through Day 35. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Caroboxymaltose0/40 (0%)0/40 (0%)0/40 (0%)
Oral Ferrous Sulfate0/39 (0%)0/39 (0%)0/39 (0%)

Baseline characteristics

Age, Customized
Age, Customized(years)Ferric CaroboxymaltoseOral Ferrous SulfateTotal
Mean12.5 ± .512.8 ± .412.6 ± .5
Sex: Female, Male
Sex: Female, Male(Participants)Ferric CaroboxymaltoseOral Ferrous SulfateTotal
Female333063
Male7916
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ferric CaroboxymaltoseOral Ferrous SulfateTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American549
White353469
More than one race000
Unknown or Not Reported000
08

Study locations

16 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • International Research Partners, Inc.
    Doral, Florida 33122, United States
  • ProHealth Research Center
    Doral, Florida 33166, United States
  • South Florida Research Phase I-IV
    Miami Springs, Florida 33166, United States
  • Garden Medical Research, Inc.
    Miami, Florida 33155, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Riley Hospital for Children,Room 4340
    Indianapolis, Indiana 46202, United States
  • Caro Health Plaza
    Caro, Michigan 48723, United States
  • Galen Research
    Chesterfield, Missouri 63005, United States
  • Tiga Pediatrics, PC
    Bronx, New York 10467, United States
  • Cincinnati Children's Hospital and Medical Center
    Cincinnati, Ohio 45229, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76101, United States
  • Baylor College of Medicine/Texas Children Hospital
    Houston, Texas 77030, United States
  • Tekton Research
    San Antonio, Texas 78240, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Dec 2020, 22 months.

Results were first posted in Jun 2022, 1 year 6 months after primary completion.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2018
First posted
May 14, 2018
StartActual
Jan 31, 2019
Primary completionActual
Dec 22, 2020
CompletionActual
Jan 29, 2021
Results first posted
Jun 22, 2022
Last update
Jun 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03523117
Responsible party
Sponsor
First posted
May 14, 2018
Start date
Jan 31, 2019
Primary completion
Dec 22, 2020
Completion
Jan 29, 2021
Results posted
Jun 22, 2022
Last update
Jun 22, 2022

Study contacts

Mark Falone
study director · American Regent, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferric carboxymaltose · Ferrous sulfate

Start the discussion